Recent advances in the search for antiviral agents against human papillomaviruses

Antiviral Therapy

Volumn 12, Issue 4, 2007, Pages 431-451

  Fradet Turcotte, Amélie ^a,b   Archambault, Jacques ^a,b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ARTEMISININ; BENZODIAZEPINE DERIVATIVE; BIPHENYLSULPHONACETIC ACID INHIBITOR; CARRAGEENAN; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYTOTOXIC AGENT; DEPSIPEPTIDE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HISTONE DEACETYLASE INHIBITOR; IMIQUIMOD; INDANDIONE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; POLYAMIDE; POLYPHENON E; PROTEIN E6; PROTEIN E7; ROSCOVITINE; UNCLASSIFIED DRUG; VALPROATE MAGNESIUM; VALPROIC ACID; VIRUS VACCINE; VORINOSTAT; WART VIRUS VACCINE;

ANUS CANCER; CANCER SURGERY; CLINICAL TRIAL; CONDYLOMA; DNA REPLICATION; DNA SYNTHESIS; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ELECTROSURGERY; EPISOME; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; SKIN DEFECT; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS REPLICATION; WART VIRUS;

ANTIVIRAL AGENTS; BASE SEQUENCE; DRUG DESIGN; FEMALE; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROTEINS; VIRAL PROTEINS;

EID: 34447249060     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (192)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-265.
2. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101:270-280.
3. Frisch M, Fenger C, van den Brule AJ, et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res 1999; 59:753-757.
4. Syrjanen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005; 32 Suppl 1:S59-S66.
5. Akgul B, Cooke JC, Storey A. HPV-associated skin disease. J Pathol 2006; 208:165-175.
6. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27.
7. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004; 78:11451-11460.
8. Clad A, Gissmann L, Meier B, Freese UK, Schwarz E. Molecular cloning and partial nucleotide sequence of human papillomavirus type 1a DNA. Virology 1982; 118:254-259.
9. Chan SY, Delius H, Halpern AL, Bernard HU. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol 1995; 69:3074-3083.
10. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7:11-22.
11. Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnurch HG, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A 1983; 80:560-563.
12. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3-8.
13. American Cancer Society [homepage on the internet]. Atlanta: American Cancer Society, Inc.; 2006. Cancer Facts and Figures 2006. Available from http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf
14. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004; 36:11-19.
15. Batson A, Meheus F, Brooke S. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries. Vaccine 2006; 24 Suppl 3:S219-S225.
16. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J 2006; 12:5.
17. Gross G. Therapy of human papillomavirus infection and associated epithelial tumors. Intervirology 1997; 40:368-377.
18. US Food and Drugs Administration. VEREGEN™ (Kunecatechins) Ointment, 15%. Bradley Pharmaceuticals, Inc. under license from MediGene AG. Application No 021902. Rockville: US Food and Drug Administration; 2006. Available from http://www.fda.gov/cder/foi/label/2006/021902lbl.pdf
19. US Food and Drug Administration [homepage on the internet]. Rockville: US Food and Drug Administration; 2006 [updated 2006 June 8, cited 8th June 2006]. GARDASIL®; Product Approval Information - Licensing Action. Merck & Co., Inc. Available from http://www.fda.gov/cber/products/hpvmer060806.htm
20. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4:46-54.
21. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-1466.
22. GlaxoSmithKline. Mississauga: GlaxoSmithKline, 2006 [updated 2006 June 5, cited 5th June 2006]. New data show cervarixTM, GSK's HPV 16/18 cervical cancer candidate vaccine is highly immunogenic and well-tolerated in women over 25 years of age. Available from http://www.gsk.ca/en/media_room/news/20060605.pdf
23. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health 2005; 37:S3-S9.
24. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006; 16:83-97.
25. Sverdrup F, Myers G. The E1 proteins. In Human papillomavirus 1997; pp. 37-53. Edited by G Myers, C Baker, K Münger, F Sverdruo, A McBride & HU Bernard. Los Alamos: Theoretical Biology and Biophysics, Los Alamos National Laboratory.
26. Frattini MG, Laimins LA. Binding of the human papillomavirus E1 origin-recognition protein is regulated through complex formation with the E2 enhancer-binding protein. Proc Natl Acad Sci U S A 1994; 91:12398-12402.
27. Mohr IJ, Clark R, Sun S, Androphy EJ, MacPherson P, Botchan MR. Targeting the E1 replication protein to the papillomavirus origin of replication by complex formation with the E2 transactivator. Science 1990; 250:1694-1699.
28. Lusky M, Hurwitz J, Seo YS. The bovine papillomavirus E2 protein modulates the assembly of but is not stably maintained in a replication- competent multimeric E1-replication origin complex. Proc Natl Acad Sci U S A 1994; 91:8895-8899.
29. Sanders CM, Stenlund A. Mechanism and requirements for bovine papillomavirus, type 1, E1 initiator complex assembly promoted by the E2 transcription factor bound to distal sites. J Biol Chem 2001; 276:23689-23699.
30. Schuck S, Stenlund A. Assembly of a double hexameric helicase. Mol Cell 2005; 20:377-389.
31. Schuck S, Stenlund A. Role of papillomavirus E1 initiator dimerization in DNA replication. J Virol 2005; 79:8661-8664.
32. Conger KL, Liu JS, Kuo SR, Chow LT, Wang TS. Human papillomavirus DNA replication. Interactions between the viral E1 protein and two subunits of human DNA polymerase α/primase. J Biol Chem 1999; 274:2696-2705.
33. Clower RV, Fisk JC, Melendy T. Papillomavirus E1 protein binds to and stimulates human topoisomerase I. J Virol 2006; 80:1584-1587.
34. Han Y, Loo YM, Militello KT, Melendy T. Interactions of the papovavirus DNA replication initiator proteins, bovine papillomavirus type 1 E1 and simian virus 40 large T antigen, with human replication protein A. J Virol 1999; 73:4899-4907.
35. Loo YM, Melendy T. Recruitment of replication protein A by the papillomavirus E1 protein and modulation by single-stranded DNA. J Virol 2004; 78:1605-1615.
36. Masterson PJ, Stanley MA, Lewis AP, Romanos MA. A C-terminal helicase domain of the human papillomavirus E1 protein binds E2 and the DNA polymerase α-primase p68 subunit. J Virol 1998; 72:7407-7419.
37. Park P, Copeland W, Yang L, Wang T, Botchan MR, Mohr IJ. The cellular DNA polymerase α-primase is required for papillomavirus DNA replication and associates with the viral E1 helicase. Proc Natl Acad Sci U S A 1994; 91:8700-8704.
38. Hegde RS. The papillomavirus E2 proteins: structure, function, and biology. Annu Rev Biophys Biomol Struct 2002; 31:343-360.
39. Ilves I, Kivi S, Ustav M. Long-term episomal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which is mediated by the viral E2 protein and its binding sites. J Virol 1999; 73:4404-4412.
40. Frattini MG, Laimins LA. The role of the E1 and E2 proteins in the replication of human papillomavirus type 31b. Virology 1994; 204:799-804.
41. Wu X, Xiao W, Brandsma JL. Papilloma formation by cottontail rabbit papillomavirus requires E1 and E2 regulatory genes in addition to E6 and E7 transforming genes. J Virol 1994; 68:6097-6102.
42. Peh WL, Brandsma JL, Christensen ND, Cladel NM, Wu X, Doorbar J. The viral E4 protein is required for the completion of the cottontail rabbit papillomavirus productive cycle in vivo. J Virol 2004; 78:2142-2151.
43. Brandsma JL, Yang ZH, DiMaio D, Barthold SW, Johnson E, Xiao W. The putative E5 open reading frame of cotton-tail rabbit papillomavirus is dispensable for papilloma formation in domestic rabbits. J Virol 1992; 66:6204-6207.
44. Ruesch MN, Stubenrauch F, Laimins LA. Activation of papillomavirus late gene transcription and genome amplification upon differentiation in semisolid medium is coincident with expression of involucrin and transglutaminase but not keratin-10. J Virol 1998; 72:5016-5024.
45. McBride AA, McPhillips MG & Oliveira JG. Brd4: tethering, segregation and beyond. Trends Microbiol 2004; 12:527-529.
46. Howley PM, Lowy DR. Papillomaviruses and their replication. In Fields Virology, vol. 2, 4th edn 2001; pp. 2197-2229. Edited by BN Fields, DM Knipe & PM Howley. Philadelphia: Lippincott Williams & Wilkins.
47. Kovelman R, Bilter GK, Glezer E, Tsou AY, Barbosa MS. Enhanced transcriptional activation by E2 proteins from the oncogenic human papillomaviruses. J Virol 1996; 70:7549-7560.
48. Demeret C, Desaintes C, Yaniv M, Thierry F. Different mechanisms contribute to the E2-mediated transcriptional repression of human papillomavirus type 18 viral oncogenes. J Virol 1997; 71:9343-9349.
49. Thierry F, Yaniv M. The BPV1-E2 trans-acting protein can be either an activator or a repressor of the HPV18 regulatory region. EMBO J 1987; 6:3391-3397.
50. Bernard BA, Bailly C, Lenoir MC, Darmon M, Thierry F, Yaniv M. The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV18 regulatory region in human keratinocytes. J Virol 1989; 63:4317-4324.
51. Soeda E, Ferran MC, Baker CC, McBride AA. Repression of HPV16 early region transcription by the E2 protein. Virology 2006; 351:29-41.
52. Lehman CW, Botchan MR. Segregation of viral plasmids depends on tethering to chromosomes and is regulated by phosphorylation. Proc Natl Acad Sci U S A 1998; 95:4338-4343.
53. Skiadopoulos MH, McBride AA. Bovine papillomavirus type 1 genomes and the E2 transactivator protein are closely associated with mitotic chromatin. J Virol 1998; 72:2079-2088.
54. Bastien N, McBride AA. Interaction of the papillomavirus E2 protein with mitotic chromosomes. Virology 2000; 270:124-134.
55. Dao LD, Duffy A, Van Tine BA, et al. Dynamic localization of the human papillomavirus type 11 origin-binding protein E2 through mitosis while in association with the spindle apparatus. J Virol 2006; 80:4792-4800.
56. Van Tine BA, Dao LD, Wu SY, et al. Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning. Proc Natl Acad Sci U S A 2004; 101:4030-4035.
57. Schweiger MR, You J, Howley PM. Bromodomain protein 4 mediates the papillomavirus E2 transcriptional activation function. J Virol 2006; 80:4276-4285.
58. Senechal H, Poirier GG, Coulombe B, Laimins LA, Archambault J. Amino acid substitutions that specifically impair the transcriptional activity of papillomavirus E2 affect binding to the long isoform of Brd4. Virology 2007; 358:10-17.
59. Abbate EA, Voitenleitner C, Botchan MR. Structure of the papillomavirus DNA-tethering complex E2:Brd4 and a peptide that ablates HPV chromosomal association. Mol Cell 2006; 24:877-889.
60. Wu SY, Lee AY, Hou SY, et al. Brd4 links chromatin targeting to HPV transcriptional silencing. Genes Dev 2006; 20:2383-2396.
61. You J, Schweiger MR, Howley PM. Inhibition of E2 binding to Brd4 enhances viral genome loss and phenotypic reversion of bovine papilloma virus-transformed cells. J Virol 2005; 79:14956-14961.
62. Ilves I, Maemets K, Silla T, Janikson K, Ustav M. Brd4 is involved in multiple processes of the bovine papillomavirus type 1 life cycle. J Virol 2006; 80:3660-3665.
63. Brannon AR, Maresca JA, Boeke JD, Basrai MA, McBride AA. Reconstitution of papillomavirus E2-mediated plasmid maintenance in Saccharomyces cerevisiae by the Brd4 bromodomain protein. Proc Natl Acad Sci U S A 2005; 102:2998-3003.
64. You J, Croyle JL, Nishimura A, Ozato K, Howley PM. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 2004; 117:349-360.
65. McPhillips MG, Oliveira JG, Spindler JE, Mitra R, McBride AA. Brd4 is required for E2-mediated transcriptional activation but not genome partitioning of all papillomaviruses. J Virol 2006; 80:9530-9543.
66. McPhillips MG, Ozato K, McBride AA. Interaction of bovine papillomavirus E2 protein with Brd4 stabilizes its association with chromatin. J Virol 2005; 79:8920-8932.
67. Baxter MK, McPhillips MG, Ozato K, McBride AA. The mitotic chromosome binding activity of the papillomavirus E2 protein correlates with interaction with the cellular chromosomal protein, Brd4. J Virol 2005; 79:4806-4818.
68. Stubenrauch F, Colbert AM, Laimins LA. Transactivation by the E2 protein of oncogenic human papillomavirus type 31 is not essential for early and late viral functions. J Virol 1998; 72:8115-8123.
69. Jeckel S, Huber E, Stubenrauch F, Iftner T. A transactivator function of cottontail rabbit papillomavirus E2 is essential for tumor induction in rabbits. J Virol 2002; 76:11209-11215.
70. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003; 77:1551-1563.
71. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8:3905-3910.
72. Gonzalez SL, Stremlau M, He X, Basile JR, Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol 2001; 75:7583-7591.
73. Scheffner M, Whitaker NJ. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 2003; 13:59-67.
74. Moon MS, Lee CJ, Um SJ, Park IS, Yang JM, Hwang ES. Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells. Gynecol Oncol 2001; 80:168-175.
75. Nishimura A, Nakahara T, Ueno T, et al. Requirement of E7 oncoprotein for viability of HeLa cells. Microbes Infect 2006; 8:984-993.
76. Yamato K, Fen J, Kobuchi H, et al. Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Cancer Gene Ther 2006; 13:234-241.
77. Longworth MS, Laimins LA. The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J Virol 2004; 78:3533-3541.
78. Collins AS, Nakahara T, Do A, Lambert PF. Interactions with pocket proteins contribute to the role of human papillomavirus type 16 E7 in the papillomavirus life cycle. J Virol 2005; 79:14769-14780.
79. Defeo-Jones D, Vuocolo GA, Haskell KM, et al. Papillomavirus E7 protein binding to the retinoblastoma protein is not required for viral induction of warts. J Virol 1993; 67:716-725.
80. Thomas JT, Hubert WG, Ruesch MN, Laimins LA. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc Natl Acad Sci U S A 1999; 96:8449-8454.
81. Massimi P, Gammoh N, Thomas M, Banks L. HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation. Oncogene 2004; 23:8033-8039.
82. Glaunsinger BA, Lee SS, Thomas M, Banks L, Javier R. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 2000; 19:5270-5280.
83. Thomas M, Laura R, Hepner K, et al. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 2002; 21:5088-5096.
84. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001; 20:7874-7887.
85. Woods DF, Hough C, Peel D, Callaini G, Bryant PJ. Dlg protein is required for junction structure, cell polarity, and proliferation control in Drosophila epithelia. J Cell Biol 1996; 134:1469-1482.
86. Bilder D, Li M, Perrimon N. Cooperative regulation of cell polarity and growth by Drosophila tumor suppressors. Science 2000; 289:113-116.
87. Bilder D, Perrimon N. Localization of apical epithelial determinants by the basolateral PDZ protein Scribble. Nature 2000; 403:676-680.
88. Fanning AS, Anderson JM. PDZ domains: fundamental building blocks in the organization of protein complexes at the plasma membrane. J Clin Invest 1999; 103:767-772.
89. Borg JP. hScrib: un nouveau suppresseur de tumeur a l'horizon [hScrib: a potential novel tumor suppressor]. Pathol Biol (Paris) 2004; 52:328-331. French.
90. Lee C, Laimins LA. Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. J Virol 2004; 78:12366-12377.
91. Nguyen ML, Nguyen MM, Lee D, Griep AE, Lambert PF. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol 2003; 77:6957-6964.
92. Nguyen MM, Nguyen ML, Caruana G, Bernstein A, Lambert PF, Griep AE. Requirement of PDZ-containing proteins for cell cycle regulation and differentiation in the mouse lens epithelium. Mol Cell Biol 2003; 23:8970-8981.
93. Berg M, Stenlund A. Functional interactions between papillomavirus E1 and E2 proteins. J Virol. 1997; 71:3853-3863.
94. Sanders CM, Stenlund A. Recruitment and loading of the E1 initiator protein: an ATP-dependent process catalysed by a transcription factor. EMBO J 1998; 17:7044-7055.
95. Blitz IL, Laimins LA. The 68-kilodalton E1 protein of bovine papillomavirus is a DNA binding phosphoprotein which associates with the E2 transcriptional activator in vitro. J Virol 1991; 65:649-656.
96. Bonne-Andrea C, Tillier F, McShan GD, Wilson VG, Clertant P. Bovine papillomavirus type 1 DNA replication: the transcriptional activator E2 acts in vitro as a specificity factor. J Virol 1997; 71:6805-6815.
97. Seo YS, Muller F, Lusky M, et al. Bovine papilloma virus (BPV)-encoded E2 protein enhances binding of E1 protein to the BPV replication origin. Proc Natl Acad Sci U S A 1993; 90:2865-2869.
98. Yang L, Li R, Mohr IJ, Clark R, Botchan MR. Activation of BPV-1 replication in vitro by the transcription factor E2. Nature 1991; 353:628-632.
99. Yoakim C, Ogilvie WW, Goudreau N, et al. Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-Origin DNA complex. Bioorg Med Chem Lett 2003; 13:2539-2541.
100. White PW, Titolo S, Brault K, et al. Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1-E2 protein interaction. J Biol Chem 2003; 278:26765-26772.
101. Wang Y, Coulombe R, Cameron DR, et al. Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor. J Biol Chem 2004; 279:6976-6985.
102. Davidson W, McGibbon GA, White PW, et al. Characterization of the binding site for inhibitors of the HPV11 E1-E2 protein interaction on the E2 transactivation domain by photoaffinity labeling and mass spectrometry. Anal Chem 2004; 76:2095-2102.
103. Abbate EA, Berger JM, Botchan MR. The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2. Genes Dev 2004; 18:1981-1996.
104. Sedman T, Sedman J, Stenlund A. Binding of the E1 and E2 proteins to the origin of replication of bovine papillomavirus. J Virol 1997; 71:2887-2896.
105. Chen G, Stenlund A. Characterization of the DNA-binding domain of the bovine papillomavirus replication initiator E1. J Virol 1998; 72:2567-2576.
106. Sun YN, Lu JZ, McCance DJ. Mapping of HPV-11 E1 binding site and determination of other important cis elements for replication of the origin. Virology 1996; 216:219-222.
107. Holt SE, Wilson VG. Mutational analysis of the 18-base-pair inverted repeat element at the bovine papillomavirus origin of replication: identification of critical sequences for E1 binding and in vivo replication. J Virol 1995; 69:6525-6532.
108. Titolo S, Brault K, Majewski J, White PW, Archambault J. Characterization of the minimal DNA binding domain of the human papillomavirus e1 helicase: fluorescence anisotropy studies and characterization of a dimerization-defective mutant protein. J Virol 2003; 77:5178-5191.
109. Schaal TD, Mallet WG, McMinn DL, et al. Inhibition of human papilloma virus E2 DNA binding protein by covalently linked polyamides. Nucleic Acids Res 2003; 31:1282-1291.
110. Bashkin J, Fisher C. Potential new treatment for human papillomavirus: Scientists from UM-St. Louis, NanoVir make discovery. 19th International Conference for Antiviral Research. 7-11 May 2006, San Juan, Puerto Rico. Abstract 35. Available from http://m114.phrm.cf.ac.uk/ISAR2/2006.sanjuan.icar. program.pdf
111. Dervan PB, Burli RW. Sequence-specific DNA recognition by polyamides. Curr Opin Chem Biol 1999; 3:688-693.
112. Zimmerman JM, Maher LJ III. Solution measurement of DNA curvature in papillomavirus E2 binding sites. Nucleic Acids Res 2003; 31:5134-5139.
113. Bedrosian CL, Bastia D. The DNA-binding domain of HPV-16 E2 protein interaction with the viral enhancer: protein-induced DNA bending and role of the nonconserved core sequence in binding site affinity. Virology 1990; 174:557-575.
114. Wilson VG, West M, Woytek K, Rangasamy D. Papillomavirus E1 proteins: form, function, and features. Virus Genes 2002; 24:275-290.
115. Stenlund A. Initiation of DNA replication: lessons from viral initiator proteins. Nat Rev Mol Cell Biol 2003; 4:777-785.
116. Rocque WJ, Porter DJ, Barnes JA, et al. Replication-associated activities of purified human papillomavirus type 11 E1 helicase. Protein Expr Purif 2000; 18:148-159.
117. Titolo S, Pelletier A, Sauve F, et al. Role of the ATP-binding domain of the human papillomavirus type 11 E1 helicase in E2-dependent binding to the origin. J Virol 1999; 73:5282-5293.
118. Titolo S, Pelletier A, Pulichino AM, et al. Identification of domains of the human papillomavirus type 11 E1 helicase involved in oligomerization and binding to the viral origin. J Virol 2000; 74:7349-7361.
119. White PW, Pelletier A, Brault K, et al. Characterization of recombinant HPV6 and 11 E1 helicases: effect of ATP on the interaction of E1 with E2 and mapping of a minimal helicase domain. J Biol Chem 2001; 276:22426-22438.
120. Sedman J, Stenlund A. The papillomavirus E1 protein forms a DNA-dependent hexameric complex with ATPase and DNA helicase activities. J Virol 1998; 72:6893-6897.
121. Hughes FJ, Romanos MA. E1 protein of human papillomavirus is a DNA helicase/ATPase. Nucleic Acids Res 1993; 21:5817-5823.
122. Jenkins O, Earnshaw D, Sarginson G, et al. Characterization of the helicase and ATPase activity of human papillomavirus type 6b E1 protein. J Gen Virol 1996; 77:1805-1809.
123. Santucci S, Bonne-Andrea C, Clertant P. Bovine papillomavirus type 1 E1 ATPase activity does not depend on binding to DNA nor to viral E2 protein. J Gen Virol 1995; 76:1129-1140.
124. Amin AA, Titolo S, Pelletier A, Fink D, Cordingley MG, Archambault J. Identification of domains of the HPV11 E1 protein required for DNA replication in vitro. Virology 2000; 272:137-150.
125. Jeffery JA, Sharom JR, Fazekas M, et al. An ATPase assay using scintillation proximity beads for high-throughput screening or kinetic analysis. Anal Biochem 2002; 304:55-62.
126. Faucher AM, White PW, Brochu C, Grand-Maitre C, Rancourt J, Fazal G. Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase. J Med Chem 2004; 47:18-21.
127. White PW, Faucher AM, Massariol MI, et al. Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486. Antimicrob Agents Chemother 2005; 49:4834-4842.
128. Hurst DN, Jones PS, Parkes KEB, Parratt MJ, Wilson FX, inventors; Hoffmann-La Roche Inc., assignee. Inhibitors of HPV E1 helicase enzyme. United State patent US 6703387. 2004 March 9.
129. Be X, Hong Y, Wei J, Androphy EJ, Chen JJ, Baleja JD. Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. Biochemistry 2001; 40:1293-1299.
130. Baleja JD, Cherry JJ, Liu Z, et al. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antivir Res 2006; 72:49-59.
131. Sterlinko GH, Weber M, Elston R, et al. Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides. J Mol Biol 2004; 335:971-985.
132. Liu Y, Liu Z, Androphy E, Chen J, Baleja JD. Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus. Biochemistry 2004; 43:7421-7431.
133. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delhi Rev 2001; 46:3-26.
134. Nomine Y, Masson M, Charbonnier S, et al. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 2006; 21:665-678.
135. Zhang B, Chen W, Roman A. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc Natl Acad Sci U S A 2006; 103:437-442.
136. Longworth MS, Wilson R, Laimins LA. HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs. EMBO J 2005; 24:1821-1830.
137. Brehm A, Nielsen SJ, Miska EA, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999; 18:2449-2458.
138. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000; 275:6764-6769.
139. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1:194-202.
140. Finzer P, Ventz R, Kuntzen C, Seibert N, Soto U, Rosl F. Growth arrest of HPV-positive cells after histone deacetylase inhibition is independent of E6/E7 oncogene expression. Virology 2002; 304:265-273.
141. Finzer P, Kuntzen C, Soto U, zur Hausen H, Rosl F. Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 2001; 20:4768-4776.
142. Finzer P, Krueger A, Stohr M, et al. HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway. Oncogene 2004; 23:4807-4817.
143. Duenas-Gonzalez A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 2005; b:38.
144. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005; 40:1-13.
145. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45:495-528.
146. 2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem 2004; 47:467-474.
147. Marks PA, Richon VM, Rifkind RA. Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds. Int J Hematol 1996; 63:1-17.
148. Suzuki T, Matsuura A, Kouketsu A, Nakagawa H, Miyata N. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. Bioorg Med Chem Lett 2005; 15:331-335.
149. Suzuki T, Nagano Y, Kouketsu A, et al. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem 2005; 48:1019-1032.
150. Suzuki T, Ando T, Tsuchiya K, et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999; 42:3001-3003.
151. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998; 241:126-133.
152. Lin HY, Chen CS, Lin SP, Weng JR, Chen CS. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006; 26:397-413.
153. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370:737-749.
154. Hildmann C, Wegener D, Riester D, et al. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J Biotechnol 2006; 124:258-270.
155. Chavez-Bianco A, Perez-Plasencia C, Perez-Cardenas E, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006; 6:2.
156. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45:495-528.
157. Chavez-Bianco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A Phase I study. Mol Cancer 2005; 4:22.
158. He W, Staples D, Smith C, Fisher C. Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J Virol 2003; 77:10566- 10574.
159. Duensing S, Munger K. Centrosome abnormalities and genomic instability induced by human papillomavirus oncoproteins. Prog Cell Cycle Res 2003; 5:383-391.
160. Duensing S, Munger K. Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability. Oncogene 2002; 21:6241-6248.
161. Duensing S, Duensing A, Flores ER, Do A, Lambert PF, Munger K. Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. J Virol 2001; 75:7712-7716.
162. Duensing S, Lee LY, Duensing A, et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci U S A 2000; 97:10002-10007.
163. Lin BY, Ma T, Liu JS, et al. HeLa cells are phenotypically limiting in cyclin E/CDK2 for efficient human papillomavirus DNA replication. J Biol Chem 2000; 275:6167-6174.
164. Ma T, Zou N, Lin BY, Chow LT, Harper JW. Interaction between cyclin-dependent kinases and human papillomavirus replication-initiation protein E1 is required for efficient viral replication. Proc Natl Acad Sci U S A 1999; 96:382-387.
165. Cueille N, Nougarede R, Mechali F, Philippe M, Bonne-Andrea C. Functional interaction between the bovine papillomavirus virus type 1 replicative helicase E1 and cyclin E-Cdk2. J Virol 1998; 72:7255-7262.
166. Hsu CY, Mechali F, Bonne-Andrea C. Nucleocytoplasmic shuttling of bovine papillomavirus E1 helicase downregulates viral DNA replication in S phase. J Virol 2007; 81:384-394.
167. Deng W, Lin BY, Jin G, et al. Cyclin/CDK regulates the nucleocytoplasmic localization of the human papillomavirus E1 DNA helicase. J Virol 2004; 78:13954-13965.
168. Schang LM. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim Biophys Acta 2004; 1697:197-209.
169. Schang LM. Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother 2002; 50:779-792.
170. Vitali L, Yakisich JS, Vita MF, et al. Roscovitine inhibits ongoing DNA synthesis in human cervical cancer. Cancer Lett 2002; 180:7-12.
171. Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999; 1:60-67.
172. Duensing S, Duensing A, Lee DC, et al. Cyclin-dependent kinase inhibitor indirubin-3′-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 2004; 23:8206-8215.
173. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243:527-536.
174. Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol 2006; 36:1427-1441.
175. Disbrow GL, Baege AC, Kierpiec KA, et al. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res 2005; 65:10854-10861.
176. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32:1655-1660.
177. O'Neill PM, Posner GH. A medicinal chemistry perspective on artemisinin and related endoperoxides. J Med Chem 2004; 47:2945-2964.
178. Bernard HU. Gene expression of genital human papillomaviruses and considerations on potential antiviral approaches. Antivir Ther 2002; 7:219-237.
179. Demeret C, Le Moal M, Yaniv M, Thierry F. Control of HPV 18 DNA replication by cellular and viral transcription factors. Nucleic Acids Res 1995; 23:4777-4784.
180. Gloss B, Bernard HU. The E6/E7 promoter of human papillomavirus type 16 is activated in the absence of E2 proteins by a sequence-aberrant Sp1 distal element. J Virol 1990; 64:5577-5584.
181. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188:143-160.
182. Craigo J, Callahan M, Huang RC, DeLucia AL. Inhibition of human papillomavirus type 16 gene expression by nordihydroguaiaretic acid plant lignan derivatives. Antivir Res 2000; 47:19-28.
183. Gloss B, Bernard HU. The E6/E7 promoter of human papillomavirus type 16 is activated in the absence of E2 proteins by a sequence-aberrant Sp1 distal element. J Virol 1990; 64:5577-5584.
184. Butz K, Hoppe-Seyler F. Transcriptional control of human papillomavirus (HPV) oncogene expression: composition of the HPV type 18 upstream regulatory region. J Virol 1993; 67:6476-6486.
185. O'Connor M, Chan SY, Bernard HU. Transcription factor binding sites in the long control region of genital HPVs. In Human Papillomaviruses 1995 Compendium, part III-A 1995, pp. 21-40. Edited by G Myers, HU Bernard, H Delius, C Baker, J Icenogle, A Halpern & C Wheeler. Los Alamos: Los Alamos National Laboratory.
186. Heller JD, Kuo J, Wu TC, Kast WM, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo. Cancer Res 2001; 61:5499-5504.
187. Chang CC, Heller JD, Kuo J, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A 2004; 101:13239- 13244.
188. Huang RC, Li Y, Giza PE, et al. Novel antiviral agent tetraglycylated nordihydroguaiaretic acid hydrochloride as a host-dependent viral inhibitor. Antivir Res 2003; 58:57-64.
189. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2006; 2:e69.
190. Giroglou T, Sapp M, Lane C, et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001; 19:1783-1793.
191. Joyce JG, Tung JS, Przysiecki CT, et al. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 1999; 274:5810-5822.
192. Tobacman JK. Review of harmful gastrointestinal effects of carrageenan in animal experiments. Environ Health Perspect 2001; 109:983-994.